REGISTERED NUMBER: 11331809 (England and Wales)

Unaudited Financial Statements for the Year Ended 31 December 2025

for

Cannbiorex Pharma Limited

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTOR:

Mr M Squires

REGISTERED OFFICE:

71-75 Shelton Street

London

WC2H 9JQ

REGISTERED NUMBER:

11331809 (England and Wales)

ACCOUNTANTS:

KSG Accountants Ltd

4 Somerset Way

Iver

Buckinghamshire

SL0 9AF

CURRENT ASSETS

Debtors

5

14,646,444

14,564,479

Cash at bank

8,683

14,294

14,655,127

14,578,773

CREDITORS

Amounts falling due within one year

6

25,416,962

25,496,967

NET CURRENT LIABILITIES

(10,761,835

)

(10,918,194

)

TOTAL ASSETS LESS CURRENT LIABILITIES

(10,761,835

)

(10,918,194

)

CREDITORS

Amounts falling due after more than one year

7

-

5,286

NET LIABILITIES

(10,761,835

)

(10,923,480

)

CAPITAL AND RESERVES

Called up share capital

1

1

Retained earnings

(10,761,836

)

(10,923,481

)

(10,761,835

)

(10,923,480

)

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 23 April 2026 and were signed by:

Mr M Squires - Director

1.	STATUTORY INFORMATION

Cannbiorex Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of thirty years.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2024 - 1 ) .

4.	INTANGIBLE FIXED ASSETS

Other

intangible

assets

£

COST

At 1 January 2025

and 31 December 2025

1,227,607

AMORTISATION

At 1 January 2025

and 31 December 2025

1,227,607

NET BOOK VALUE

At 31 December 2025

-

At 31 December 2024

-

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.12.25

31.12.24

£

£

Other debtors

14,646,444

14,564,479

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.12.25

31.12.24

£

£

Bank loans and overdrafts

5,182

10,375

Trade creditors

887,740

1,480,743

Other creditors

24,524,040

24,005,849

25,416,962

25,496,967

7.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

31.12.25

31.12.24

£

£

Bank loans

-

5,286

Amounts falling due in more than five years:

Repayable by instalments

Bank loans more 5 yr by instal

-

5,286

8.	RELATED PARTY DISCLOSURES

The company is controlled by Cannbiorex Pharmaceuticals Corp.